Markets
Bubbles floating on a light blue background
Getty Images
FROTHY HINTS

Wall Street is starting to warn about the stock market

But very, very quietly.

Matt Phillips
7/22/25 1:30PM

Nobody on Wall Street ever got a fat bonus scaring people out of the market.

That’s logical. Wall Street is largely in the business of helping companies sell securities to the public and coaxing corporations into making deals, both of which generate juicy fees.

Having one of your market analysts screaming that equity market end times are nigh isn’t exactly helpful background music as your bankers try to build a book of orders for that upcoming IPO. In fact, such a stark warning would almost certainly see our analyst counseled on pursuing other careers.

But there’s career risk for analysts in keeping quiet, too. After all, if they do see reasons to be worried about the market but say nothing, and the market does tank, that’s an equally bad look.

So, what’s a career-conscious analyst to do?

It’s obvious. Issue warnings. Raise concerns. Heck, even wave a tiny red flag or two. But just do it very, very quietly.

That way, if something does go wrong, you can always refer clients to back to your comments about the growing pressures on the market, just before the big crack came. On the other hand, if the market keeps climbing, you can shrug off those bearish moments as well-reasoned notes of caution.

Anyway, with the SPDR S&P 500 ETF hovering around new highs, after a more than 25% rally from the worst of April’s tariff-induced drop, you can start to hear these ever-so-faint words of warning from the Street.

“The pockets of exuberance are growing,” Deutsche Bank analysts recently wrote. They hastened to add, “However, other measures of exuberance remain subdued.”

In a note Tuesday, Bank of America analysts couched their concerns like this: “Although we’re not seeing classic signs today of a blow-off top at the broad index level, pockets of the market — e.g., recent IPOs CRWV & CRCL — are exhibiting bubble-like dynamics.”

And on Monday, Morgan Stanley’s chief US equity analyst suggested clients “stay bullish while acknowledging the risks,” and nodded to “some recent froth in lower quality names.”

To be fair, JPMorgan analysts did not equivocate much in a note this week when they wrote that extreme levels of crowding into riskiest, most volatile kinds high-beta stocks “not only presents a risk for this crowded segment, but is also a red flag for the broader market implying there is rising complacency in the short term.”

But clearly, folks who spend their lives keeping an eye on the market are seeing lots of behaviors that look, for lack of a better word, a bit “toppy.”

That is, there’s a lot of highly speculative behavior in the market that can, sometimes, come before a fall. Just look at the resurgence of meme stock mania in shares like Opendoor or, today’s edition, Kohl’s. Or the frenetic trading of crypto and crypto-related stocks. Or the return of SPACs.

And, while nobody cares about valuation anymore, it’s worth noting that the stock market is extremely expensive by conventional metrics like price-to-forward-earnings and price-to-sales ratios.

The S&P 500’s forward P/E multiple is currently 22.4x. It’s only been higher on a sustainable basis during the pandemic-era trading boom and during the tech bubble of the late 1990s. Its price-to-sales ratio of more than 3x is likewise in dot-com bubble territory, with some market leaders, like the market’s best-forming stock, Palantir, sporting valuations that appear objectively insane.

Now time for some mealymouthed hedging of my own. This is not investment advice! Stock markets that are expensive can continue to get more expensive, meaning there’s more upside to be had. And of course it’s always possible that the market is correctly sniffing out the profit potential of the future before analysts can find a way to properly pencil it in to their own quantitative models.

On a personal note, I know from long experience that I have a tendency to see potential disasters everywhere. (I think it’s my Irish side.) Even if they do eventually materialize, it can take a good long while. In other words, I’m a bit risk averse and not much of a speculator.

But the recent whispered warnings from Wall Street suggest I’m not the only one who’s a bit jumpy after the recent rally.

More Markets

See all Markets
markets
Luke Kawa
9/5/25

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

markets

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.